Literature DB >> 21593019

Evaluation of soluble P-selectin as a marker for the diagnosis of deep venous thrombosis.

Eduardo Ramacciotti1, Susan Blackburn, Angela E Hawley, Frank Vandy, Nicole Ballard-Lipka, Cathy Stabler, Nichole Baker, Kenneth E Guire, John E Rectenwald, Peter K Henke, Daniel D Myers, Thomas W Wakefield.   

Abstract

OBJECTIVE: The combination of D-dimer and Wells score can exclude, but not confirm, the diagnosis of deep venous thrombosis (DVT). Since thrombosis and inflammation are interrelated, we evaluated the combination of soluble P-selectin (sPsel) with other inflammatory biomarkers for the diagnosis of DVT.
METHODS: Sixty-two positive and one hundred and sixteen patients with negative DVT, by duplex scan, were prospectively evaluated for sPsel, D-dimer, C-reactive protein (CRP), microparticles (MPs; total, leukocyte, and platelet-derived and tissue factor positive microparticles), and clinical Wells score.
RESULTS: Biomarkers and clinical scores that differentiated DVT positives from negatives were sPsel (87.3 vs 53.4 ng/mL, P < .0001), D-dimer (5.8 vs 2.1 mg/ L, P < .0001), CRP (2.1 vs 0.8 μg/mL, P < .0005), and Wells score (3.2 vs 2.0, P < .0001). For MP analysis, platelet-derived MPs were found to differentiate DVT from negatives. Using multivariable logistic regression, a combination of sPsel and Wells score could establish the diagnosis of DVT (cut point ≥ 90 ng/mL + Wells ≥ 2), with a specificity of 96% and positive predictive value (PPV) of 100%, and could exclude DVT diagnosis (cut point ≤ 60 ng/mL and Wells <2) with a sensitivity of 99%, a specificity of 33%, and a negative predictive value (NPV) of 96%.
CONCLUSION: This study establishes a biomarker and clinical profile combination that can both confirm and exclude the diagnosis of DVT.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21593019      PMCID: PMC3306250          DOI: 10.1177/1076029611405032

Source DB:  PubMed          Journal:  Clin Appl Thromb Hemost        ISSN: 1076-0296            Impact factor:   2.389


  30 in total

Review 1.  Thromboembolic diseases.

Authors:  Thomas W Wakefield; Joseph Caprini; Anthony J Comerota
Journal:  Curr Probl Surg       Date:  2008-12       Impact factor: 1.909

2.  Circulating procoagulant microparticles in patients with venous thromboembolism.

Authors:  Cihan Ay; Jean-Marie Freyssinet; Thomas Sailer; Rainer Vormittag; Ingrid Pabinger
Journal:  Thromb Res       Date:  2008-11-07       Impact factor: 3.944

3.  D-dimer, P-selectin, and microparticles: novel markers to predict deep venous thrombosis. A pilot study.

Authors:  John E Rectenwald; Daniel D Myers; Angela E Hawley; Christopher Longo; Peter K Henke; Kenneth E Guire; Alvin H Schmaier; Thomas W Wakefield
Journal:  Thromb Haemost       Date:  2005-12       Impact factor: 5.249

4.  Combined use of D-dimer and P-selectin for the diagnosis of splenic or portal vein thrombosis following splenectomy.

Authors:  Li Wang; Gui-Jie Liu; Yan-Xin Chen; Huai-Ping Dong; Yan-Qiang Zhang; Le-Xin Wang
Journal:  Thromb Res       Date:  2010-01-15       Impact factor: 3.944

5.  The role of soluble cell adhesion molecules in patients with suspected deep vein thrombosis.

Authors:  Robert A Bucek; Markus Reiter; Peter Quehenberger; Erich Minar; Mehrdad Baghestanian
Journal:  Blood Coagul Fibrinolysis       Date:  2003-10       Impact factor: 1.276

6.  Leukocyte- and platelet-derived microparticles correlate with thrombus weight and tissue factor activity in an experimental mouse model of venous thrombosis.

Authors:  Eduardo Ramacciotti; Angela E Hawley; Diana M Farris; Nicole E Ballard; Shirley K Wrobleski; Daniel D Myers; Peter K Henke; Thomas W Wakefield
Journal:  Thromb Haemost       Date:  2009-04       Impact factor: 5.249

7.  Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis.

Authors:  Philip S Wells; David R Anderson; Marc Rodger; Melissa Forgie; Clive Kearon; Jonathan Dreyer; George Kovacs; Michael Mitchell; Bernard Lewandowski; Michael J Kovacs
Journal:  N Engl J Med       Date:  2003-09-25       Impact factor: 91.245

8.  High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS).

Authors:  Cihan Ay; Ralph Simanek; Rainer Vormittag; Daniela Dunkler; Guelay Alguel; Silvia Koder; Gabriela Kornek; Christine Marosi; Oswald Wagner; Christoph Zielinski; Ingrid Pabinger
Journal:  Blood       Date:  2008-06-06       Impact factor: 22.113

Review 9.  Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism.

Authors:  Madeleine Verhovsek; James D Douketis; Qilong Yi; Sanjay Shrivastava; R Campbell Tait; Trevor Baglin; Daniela Poli; Wendy Lim
Journal:  Ann Intern Med       Date:  2008-10-07       Impact factor: 25.391

10.  Circulating P-selectin and the risk of recurrent venous thromboembolism.

Authors:  Paul A Kyrle; Gregor Hron; Sabine Eichinger; Oswald Wagner
Journal:  Thromb Haemost       Date:  2007-06       Impact factor: 5.249

View more
  29 in total

1.  Soluble P-selectin for the diagnosis of lower extremity deep venous thrombosis.

Authors:  Frank C Vandy; Cathy Stabler; Anna M Eliassen; Angela E Hawley; Kenneth E Guire; Daniel D Myers; Peter K Henke; Thomas W Wakefield
Journal:  J Vasc Surg Venous Lymphat Disord       Date:  2013-04-01

Review 2.  Statins, inflammation and deep vein thrombosis: a systematic review.

Authors:  April L Rodriguez; Brandon M Wojcik; Shirley K Wrobleski; Daniel D Myers; Thomas W Wakefield; Jose A Diaz
Journal:  J Thromb Thrombolysis       Date:  2012-05       Impact factor: 2.300

Review 3.  Microparticle analysis in disorders of hemostasis and thrombosis.

Authors:  Micah J Mooberry; Nigel S Key
Journal:  Cytometry A       Date:  2015-02-20       Impact factor: 4.355

4.  Tuning the Thromboinflammatory Response to Venous Flow Interruption by the Ectonucleotidase CD39.

Authors:  Anuli C Anyanwu; Yogendra Kanthi; Keigo Fukase; Hui Liao; Tekashi Mimura; Karl C Desch; Martin Gruca; Saabir Kaskar; Hussein Sheikh-Aden; Liguo Chi; Raymond Zhao; Vinita Yadav; Thomas W Wakefield; Matthew C Hyman; David J Pinsky
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-04       Impact factor: 8.311

5.  Rosuvastatin reduced deep vein thrombosis in ApoE gene deleted mice with hyperlipidemia through non-lipid lowering effects.

Authors:  K A Patterson; X Zhang; S K Wrobleski; A E Hawley; D A Lawrence; T W Wakefield; D D Myers; J A Diaz
Journal:  Thromb Res       Date:  2012-12-29       Impact factor: 3.944

6.  Identification of novel diagnostic biomarkers for deep venous thrombosis.

Authors:  Ashfaque A Memon; Kristina Sundquist; Mirnabi PirouziFard; Johan L Elf; Karin Strandberg; Peter J Svensson; Jan Sundquist; Bengt Zöller
Journal:  Br J Haematol       Date:  2018-04-19       Impact factor: 6.998

Review 7.  Biomarkers of deep venous thrombosis.

Authors:  Huacheng Hou; Zhijuan Ge; Pu Ying; Jin Dai; Dongquan Shi; Zhihong Xu; Dongyang Chen; Qing Jiang
Journal:  J Thromb Thrombolysis       Date:  2012-10       Impact factor: 2.300

8.  Role of P-selectin in thromboembolic events in patients with cancer.

Authors:  Lúcio Flávio Barbour Fernandes; José Humberto T G Fregnani; Célia Maria Cássaro Strunz; Adriana de Andrade Ramos Nogueira; Adhemar Longatto-Filho
Journal:  Mol Clin Oncol       Date:  2017-11-02

9.  Reply. Regarding "Impact of screening versus symptomatic measurement of deep vein thrombosis in a national quality improvement registry".

Authors:  Randall R De Martino; Philip P Goodney
Journal:  J Vasc Surg       Date:  2013-01       Impact factor: 4.268

10.  Prothrombotic effects of thrombolytic therapy in a rat (Rattus norvegicus) model of venous thrombolysis.

Authors:  Katherine A Shuster; Shirley K Wrobleski; Angela E Hawley; Benedict R Lucchesi; Dorothy R Sorenson; Ingrid L Bergin; Robert E Sigler; Kenneth E Guire; Megan H Nowland; Thomas W Wakefield; Daniel D Myers
Journal:  Comp Med       Date:  2013-06       Impact factor: 0.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.